MAPK9 and neoplasm: Interestingly, when tumor samples from several of the CONKO-005 trial participants were re-analyzed, a subgroup of patients with a combination of SMAD4 loss and low Mitogen-Activated Protein Kinase 9 (MAPK9) expression benefited from the addition of Erlotinib (Hoyer et al., 2021).